Digest Network Come funziona
Network
/
Società
Vi
Non verificato

Vir Biotechnology, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniMedicina - VarieSalute

53 comunicati stampa

Guarda tutti i comunicati
26/02/2026
Eventi
Web e Social Network
Biotecnologia
Finanza
Salute
Associazioni/Professionisti
Farmaceutica
Vir Biotechnology to Participate in Upcoming Investor Conferences
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
26/02/2026
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
24/02/2026
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Vir Biotechnology Announces Proposed Public Offering of Common Stock
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
23/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
23/02/2026
Web e Social Network
Telefonia e Varie
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
09/02/2026
Biotecnologia
Finanza
Salute
Associazioni/Professionisti
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Oncologia
Web e Social Network
Mercato del lavoro
Fiere
Eventi
Analisi di mercato
Finanza
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Scienza
Medicina - Varie
Biologia
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Eventi
Web e Social Network
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
16/12/2025
Mercato del lavoro
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Eventi
Web e Social Network
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
Fonte
Vir Biotechnology, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0